Johnson & Johnson Loses Trial Over Risperdal And Male Breasts

February 2015

The Wall Street Journal reports on the first Risperdal case to go to a jury following the $2.2 billion settlement with the Department of Justice in 2013: “In a setback to Johnson & Johnson, a Philadelphia jury decided the health care giant must pay $2.5 million in damages for failing to warn that its Risperdal antipsychotic could cause gynecomastia, which is abnormal development of breasts in males. The lawsuit was brought by the family of an autistic boy who took the drug in 2002 and later developed size 46 DD breasts, according to a lawyer for the family.”